Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery / Parva Jani, Jigar Vanza, Nilima Pandya, Hemal Tandel
Aim:The manuscript describes the performance of nanoparticles loaded with antidepressant drug for nose-to-brain drug delivery.Materials & methods:Poly-lactic-co-glycolic acid-loaded nanoparticles of agomelatine were prepared by nanoprecipitation method using poloxamer 407 as stabilizer. The process parameters were optimized using factorial design.Results:The drug-loaded nanoparticles having low particle size (<200 nm) with narrow size distribution and required zeta potential (-22.7 mV) to avoid aggregation showed sustained release profile and were found to have higher permeability as observed fromex vivostudies when compared with plain drug suspension. Histopathology test showed that the optimized formulation was free from nasal toxicity on the goat nasal mucosa. Pharmacodynamic study showed significant reduction in immobility time in rats treated with the formulation which indicated antidepressant activity of the formulation.Conclusion:The prepared agomelatin-loaded poly-lactic-co-glycolic acid nanoparticles showed prominent antidepressant activity by nose-to-brain delivery as observed from various studies. Aim: Materials & methods: Results: ex vivo Conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Therapeutic Delivery - 10(2019), 11, Seite 683- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jani, Parva [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.4155/tde-2019-0060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001068288 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001068288 | ||
| 003 | DE-627 | ||
| 005 | 20230430081611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2019-0060 |2 doi | |
| 035 | |a (DE-627)KFL001068288 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2019-0060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Jani, Parva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery |c Parva Jani, Jigar Vanza, Nilima Pandya, Hemal Tandel |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:The manuscript describes the performance of nanoparticles loaded with antidepressant drug for nose-to-brain drug delivery.Materials & methods:Poly-lactic-co-glycolic acid-loaded nanoparticles of agomelatine were prepared by nanoprecipitation method using poloxamer 407 as stabilizer. The process parameters were optimized using factorial design.Results:The drug-loaded nanoparticles having low particle size (<200 nm) with narrow size distribution and required zeta potential (-22.7 mV) to avoid aggregation showed sustained release profile and were found to have higher permeability as observed fromex vivostudies when compared with plain drug suspension. Histopathology test showed that the optimized formulation was free from nasal toxicity on the goat nasal mucosa. Pharmacodynamic study showed significant reduction in immobility time in rats treated with the formulation which indicated antidepressant activity of the formulation.Conclusion:The prepared agomelatin-loaded poly-lactic-co-glycolic acid nanoparticles showed prominent antidepressant activity by nose-to-brain delivery as observed from various studies. Aim: Materials & methods: Results: ex vivo Conclusion | ||
| 700 | 1 | |a Vanza, Jigar |e verfasserin |4 aut | |
| 700 | 1 | |a Pandya, Nilima |e verfasserin |4 aut | |
| 700 | 1 | |a Tandel, Hemal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |g 10(2019), 11, Seite 683- |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:11 |g pages:683- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2019-0060 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 11 |h 683- | ||